** Shares of drug developer Atara Biotherapeutics ATRA.O fall 4.6% to $6.27 premarket
** Co says the US FDA has placed a clinical hold on trials testing its experimental cancer cell therapies
** The hold applies to studies of co's experimental cancer therapies, tabelecleucel, and ATA3219
** Co says the hold is related to the issues observed at a third-party manufacturing facility
** The FDA last week declined to approve its cancer therapy tabelecleucel to treat patients with a rare cancer that develops after organ or stem cell transplants, due to third-party manufacturing concerns
** "Atara and FDA have discussed and agreed upon the actions necessary to release the clinical holds"- ATRA
** Co says it has paused enrollment of new participants in the trials; adding that some participants "who have the potential to derive clinical benefit" can continue to receive treatment
** Up last close, stock had fallen 63.2% in the past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。